Case Comprehensive Cancer Center seminar series

The Case Comprehensive Cancer Center will host its next seminar series event Friday, April 20, from noon to 1 p.m. in the Iris S. and Bert L. Wolstein Research Building auditorium. The event will feature Suzanne J. Baker, director of the brain tumor research division; associate director for basic research and co-leader of the neurobiology and brain tumor program, comprehensive cancer center; and endowed chair in brain tumor research at St. Jude Children's Research Hospital. Baker will present “Oncohistones: Connecting Epigenetic Regulation with Gliomagenesis.”

About the speaker

The Baker laboratory is focused on elucidating the mechanisms driving diffuse high-grade glioma (HGG) in children. In children and adults, diffuse high-grade gliomas (HGGs), including Grade III anaplastic astrocytomas and Grade IV glioblastomas, share a devastating outcome, with median survival slightly greater than one year, and five-year survival of 10 to 25 percent. Although HGGs from different age groups share related gene expression signatures, histopathological features, and frequent mutations in common pathways, there are a number of distinguishing features of pediatric HGG that indicate a unique pathogenesis. While adult glioblastomas arise predominantly in the cerebral cortex, in children, a broader spectrum of anatomical locations are more frequently involved, including the occurrence of diffuse intrinsic pontine gliomas (DIPGs), which arise in the brainstem. Recent genome-wide studies from our group and others provided abundant evidence that unique selective pressures drive HGG in children compared to adults, identifying novel oncogenic mutations connecting tumorigenesis and chromatin regulation as well as developmental signaling pathways. It is now clear that there are at least several distinct subgroups of pediatric diffuse HGG based on clinical features and recurrent mutations. Ongoing work is directed towards integrating the latest genomic findings from primary human tumors to develop improved models of these disease subgroups that recapitulate the genetic and biological features of the disease for mechanistic studies and preclinical testing of selective therapies. For more information, visit cancer.case.edu/events/semseries/.